GLP-1 Jabs Linked to Rare Side Effect That’s Worse Than ‘Ozempic Face’ - The Daily Beast

What the report says

The Daily Beast reported that a new study has linked GLP-1 medications, including Ozempic, Wegovy and Mounjaro, to a higher risk of alopecia, a rare but distressing hair-loss side effect. The drugs, widely prescribed for type 2 diabetes and obesity, have already been associated with common complaints such as nausea, bloating, cramping and body changes after weight loss. The article says the new research may add hair shedding to the list of issues patients weigh before starting treatment.

According to the report, researchers at the University of Pennsylvania published the study Wednesday in The BMJ. They followed patients for an average of 2.7 years and found the elevated risk was mainly for non-scarring alopecia, a form of hair loss that does not permanently damage follicles. After at least two years of treatment, GLP-1 users had a 37% higher chance of alopecia than patients on SGLT-2 drugs and 68% higher odds than those on DPP-4 drugs, both used for type 2 diabetes.

The Daily Beast emphasized that the absolute risk remained low: about three to nine cases per 1,000 patients each year. The study recorded roughly seven annual cases among GLP-1 users, compared with five among SGLT-2 users and four among DPP-4 users. Researchers did not know from the records how severe the hair loss was, how long it lasted or whether hair regrew.

The report noted that scientists are still examining why the shedding occurs. Rapid weight loss can disrupt normal hair cycles, and dietary changes may contribute to nutrient deficiencies involving iron or zinc. Researchers said hair loss may not be physically dangerous, but it can affect self-esteem and treatment decisions.